At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
RP6530drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Randomized, Single Dose, Cross Over Study to Evaluate Food Effects on Relative Bioavailability of RP6530 Administered in Fasting and Fed Conditions in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating RP6530 for Healthy. Completed, enrolled 18 participants across 1 site.
Detailed Summary
This is a single centre, open label, randomized, two-treatment, two-period, two-sequence, single dose crossover food effect study in 18 subjects. The subjects will receive the study medication under either fed or fast during each treatment period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesCanada
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartFeb 2016
First PostedFeb 2016
Primary CompletionMar 2016
TodayJul 2026
First PostedFeb 24, 2016
Enrollment StartFeb 1, 2016
Primary CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 10.4 years ago
Interventions
RP6530drug
Single oral dose